Prelude Therapeutics INC Form 4 insider transactions

Baker Bros. Advisors LP, a significant holder and director-affiliated entity, has acquired 38,000 non-qualified stock options for Prelude Therapeutics Inc. (PRLD) with a strike price of $3.94.

Director Katina Dorton was granted 38,000 stock options in Prelude Therapeutics Inc. as part of a standard equity compensation package.

Director Martin Babler was granted 38,000 stock options in Prelude Therapeutics Inc. as part of an equity compensation award.

Director David P. Bonita was granted 38,000 stock options in Prelude Therapeutics Inc. as part of a standard compensation arrangement.

Director Victor Sandor was granted 38,000 stock options in Prelude Therapeutics Inc. as part of an equity compensation award.

Paul A. Friedman, a Director at Prelude Therapeutics Inc., has acquired stock options granting the right to buy 38,000 shares.

Prelude Therapeutics Chief Medical Officer Charles Q. Morris reports the grant of 450,000 stock options with an exercise price of $4.70.

RA Capital Management exchanged 1.4 million shares of Prelude Therapeutics common stock for pre-funded warrants.

Director David P. Bonita reports the acquisition of over 2.8 million shares of Prelude Therapeutics via a public offering.

OrbiMed Advisors and affiliated entities acquired over 2.8 million shares of Prelude Therapeutics in a public offering.

Baker Bros. Advisors LP and affiliated entities have acquired a significant number of prefunded warrants for Prelude Therapeutics Inc. common stock.

Prelude Therapeutics Inc. has granted 230,000 employee stock options to Chief Chemistry Officer Andrew Combs, vesting over four years.

Prelude Therapeutics' Chief Scientific Officer, Peggy Scherle, was granted 230,000 employee stock options with an exercise price of $2.3 per share.

Prelude Therapeutics Inc. granted its Chief Legal Officer, Chief Financial Officer, and Corporate Secretary, Bryant David Lim, 275,000 employee stock options with an exercise price of $2.30.

Prelude Therapeutics CEO Krishna Vaddi was granted 837,000 employee stock options with an exercise price of $2.30, vesting over several years.

Prelude Therapeutics Director Victor Sandor was granted 121,285 stock options with an exercise price of $1.39, vesting monthly over one year.

Prelude Therapeutics Director Katina Dorton received an award of 76,000 stock options with an exercise price of $1.19, vesting over three years.

Prelude Therapeutics' President and CMO, Jane Huang, reported the vesting of Restricted Stock Units and subsequent tax-related share disposition.

Prelude Therapeutics Inc.'s President and Chief Medical Officer, Jane Huang, reported the vesting of 9,375 Restricted Stock Units and the subsequent disposition of 3,355 shares for tax withholding purposes.

Baker Bros. Advisors and its affiliates have reported the grant of 76,000 non-qualified stock options to Dr. Paul C. Scherer, a director of Prelude Therapeutics Inc., with a strike price of $1.04 per share.

Prelude Therapeutics Inc. Director Victor Sandor was granted 38,000 stock options with an exercise price of $1.04, vesting upon the earlier of the next annual stockholder meeting or one year from the grant date.

Prelude Therapeutics Inc. Director Mardi Dier was granted 38,000 stock options with an exercise price of $1.04, vesting upon the earlier of the next annual stockholder meeting or one year from the grant date.

Prelude Therapeutics Inc. Director Paul A. Friedman was granted 38,000 stock options with an exercise price of $1.04, vesting over one year or at the next annual stockholder meeting.

David P. Bonita, a Director and 10% owner of Prelude Therapeutics Inc., was granted 38,000 stock options with an exercise price of $1.04, vesting over the next year.

Prelude Therapeutics Inc. director Martin Babler was granted 38,000 stock options with an exercise price of $1.04 per share, aligning his interests with shareholder value.

Jane Huang, President and CMO of Prelude Therapeutics, exercised stock options and disposed of shares to cover tax obligations on April 4, 2025.

Andrew Combs, Chief Chemistry Officer of Prelude Therapeutics, reports purchasing 100,000 shares of common stock at $0.6925 per share.

Prelude Therapeutics CEO Krishna Vaddi reports the acquisition of 675,000 shares of common stock at $0.6925 per share on March 25, 2025.

CEO Krishna Vaddi recently purchased additional shares of Prelude Therapeutics, signaling confidence in the company's future.

CEO Krishna Vaddi reports purchasing Prelude Therapeutics Inc. (PRLD) stock in multiple transactions.